Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;124(6):1014-1021.
doi: 10.1111/bju.14866. Epub 2019 Aug 1.

Changing clinical trends in 10 000 robot-assisted laparoscopic prostatectomy patients and impact of the 2012 US Preventive Services Task Force's statement against PSA screening

Fikret F Onol  1 , Hariharan P Ganapathi  1 , Travis Rogers  1 , Kenneth Palmer  1 , Geoff Coughlin  2 , Srinivas Samavedi  3 , Rafael Coelho  4 , Cathy Jenson  1 , Marco Sandri  5 , Bernardo Rocco  6 , Vipul Patel  1
Affiliations

Changing clinical trends in 10 000 robot-assisted laparoscopic prostatectomy patients and impact of the 2012 US Preventive Services Task Force's statement against PSA screening

Fikret F Onol et al. BJU Int. 2019 Dec.

Abstract

Objectives: To evaluate the clinical trend changes in our robot-assisted laparoscopic prostatectomy (RALP) practice and to investigate the effect of 2012 US Preventive Services Task Force (USPSTF) statement against PSA screening on these trends.

Patients and methods: Data of 10 000 RALPs performed by a single surgeon between 2002 and 2017 were retrospectively analysed. Time trends in successive 1000 cases for clinical, surgical and pathological characteristics were analysed with linear and logistic regression. Time-trend changes before and after the USPSTF's statement were compared using a logistic regression model and likelihood-ratio test.

Results: Unfavourable cancer characteristics rate, including D'Amico high risk, pathological non-organ-confined disease and Gleason score ≥4+4 increased from 11.5% to 23.3%, 14% to 42.5%, and 7.7% to 20.9%, respectively, over time (all P < 0.001). Significant time-trend changes were detected after the USPSTF's statement with an increase in the positive trend of Gleason ≥4+4 and increase in the negative trends of Gleason ≤3+4 tumours. There was a significant negative trend in the rate of full nerve-sparing (NS) with a decrease from 59.3% to 35.7%, and a significant positive trend in partial NS with an increase from 15.8% to 62.5% over time (both P < 0.001). The time-trend slope in 'high-grade' partial NS significantly decreased and 'low-grade' partial NS significantly increased after the USPSTF's statement. The overall positive surgical margin rate increased from 14.6% to 20.3% in the first vs last 1000 cases (P < 0.001), with a significant positive slope after the USPSTF's statement.

Conclusions: The proportion of high-risk patients increased in our series over time with a significant impact of the USPSTF's statement on pathological time trends. This stage migration resulted in decreased utilisation of high-quality NS and increased performance of poor-quality NS.

Keywords: #PCSM; ProstateCancer; complications; contemporary practice; outcomes; robotic surgery.

PubMed Disclaimer

References

    1. Iadeluca L, Mardekian J, Chander P, Hopps M, Makinson GT. The burden of selected cancers in the US: health behaviors and health care resource utilization. Cancer Manag Res 2017; 9: 721-30
    1. Jemal A, Ward EM, Johnson CJ et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst 2017; 109. https://doi.org/10.1093/jnci/djx030
    1. Patel VR, Sivaraman A. Current status of robot-assisted radical prostatectomy: progress is inevitable. Oncology 2012; 26: 616-9
    1. Oberlin DT, Flum AS, Lai JD, Meeks JJ. The effect of minimally invasive prostatectomy on practice patterns of American urologists. Urol Oncol 2016; 34: 255.e1-5
    1. Ploussard G. Robotic surgery in urology: facts and reality. What are the real advantages of robotic approaches for prostate cancer patients? Curr Opin Urol 2018; 28: 153-8

MeSH terms

Substances